Phase III Trial Data Reinforce Potential of Imfinzi and Lynparza and Imfinzi Regimen for Endometrial Cancer
Analysis of trial results show Imfinzi and Lynparza displayed a strong clinical benefit and more than doubled median duration of response vs. chemotherapy.
Analysis of results from the DUO-E Phase III trial have reinforced the potential of Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone, according to a press release.1
In patients assessed by mismatch repair (MMR) status, the median duration of response (DoR) in pMMR patients in the Lynparza and Imfinzi arm was more than double versus the control arm (18.7 months versus 7.6). Secondary endpoints showed consistent results for pMMR patients treated with Lynparza and Imfinzi, demonstrating a reduction in the risk of second progression or death by 32% for the combination versus the control arm.
The Imfinzi plus chemotherapy followed by Imfinzi monotherapy regimen showed consistent benefit regardless of MMR status, with the greatest benefit observed in patients with mismatch repair deficient (dMMR) disease across all secondary endpoints.
“Endometrial cancer diagnoses are rapidly rising, yet very little has changed in recent years to advance new treatments for the approximately eighty per cent of patients with advanced or recurring disease who are mismatch repair proficient,” Hye Sook Chon, gynaecologic oncologist at the Moffitt Cancer Center in Tampa, Florida, and trial investigator said in the press release. “DUO-E results demonstrate the benefit of durvalumab plus chemotherapy followed by durvalumab for patients with dMMR status and provide compelling evidence for the addition of olaparib to this regimen for patients with pMMR status.”
Imfinzi is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins. It is currently approved in several countries across multiple tumor types. Lynparza is a first-in-class PARP inhibitor, also approved across multiple tumors.
“DUO-E results have shown that adding Imfinzi to chemotherapy delivers better outcomes for patients with advanced endometrial cancer,” Susan Galbraith, executive vice president, oncology R&D, AstraZeneca said in the release. “In addition, to achieve optimal clinical benefit for patients with the greatest unmet need—those with mismatch repair proficient disease—the addition of Lynparza further enhances the effect of checkpoint inhibition in endometrial cancer.”
Reference
1. Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with mismatch repair proficient advanced or recurrent endometrial cancer. News release. March 18, 2024. Accessed March 19, 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy.html
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
A Guide to Patient Engagement & Recruitment Solutions
March 18th 2025Clinical trials have become increasingly complex over the past decades, making participant recruitment more challenging than ever. This guide explores common recruitment obstacles and offers strategies to overcome them using a patient engagement and recruitment solution.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Bridging the Gap: How Chiesi Used External Collaboration to Get Closer to Patients
March 18th 2025Chiesi partnered with Citeline to enhance clinical trial awareness and patient engagement through its FREUD initiative by launching a Trial Portfolio Website, activating 150+ sites, and generating 600+ qualified referrals—learn more about how Citeline helped improve study discoverability, streamline recruitment, and strengthen Chiesi’s presence in key therapeutic areas.
Citeline Patient Engagement & Recruitment Solutions
March 18th 2025Watch Citeline’s 15-minute presentation from Clinical Leader’s Patient Engagement & Recruitment Solutions Expo, where VP Matt Holms explores Direct-to-Data (DTD) patient recruitment. This session takes a deep dive into how complex algorithms, tokenized data, and large data assets can optimize enrollment, highlighting the importance of early strategic recruitment planning and breaking down the unique benefits and real-world applications of DTD.
